Compare Stocks

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; BioChaperone LisPram, a combination of prandial insulin with pramlintide; and BioChaperone Glucagon, an aqueous formulation of human glucagon for the treatment of hypoglycemia, as well as M1Pram, a metabolite of insulin glargine and pramlintide. Its preclinical pipeline includes products for the treatment of diabetes and obesity comprising AdoShell Islets, an implant containing islets of Langerhans; AdOral Sema, an oral delivery of semaglutide; and BioChaperone GluExe, a combination of glucagon and exenatide. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro and BioChaperone Combo in China and other Asian and Middle Eastern territories. Adocia SA was incorporated in 2005 and is headquartered in Lyon, France.

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.

Semperit Aktiengesellschaft Holding develops, produces, and sells rubber products for the medical and industrial sectors worldwide. It operates through two segments: Semperit Industrial Applications and Semperit Engineered Applications. The company provides hydraulic and industrial hoses; conveyor belts; escalator handrails; profiles for windows, doors and facades, cable car rings, and ski foils; and products for railroad superstructures and toolmaking; and precision liquid silicone parts. It offers handrails; engineered solutions; and provides elastomer and sealing profiles for windows, doors, and facades; and elastomer and wear-resistant protective sheeting. It serves agriculture, bulk transportation systems, construction, manufacturing, health care, mining and port facilities, shipping, packing, household, renewable energy and power generation, process, steel, and automotive industries. Semperit Aktiengesellschaft Holding was founded in 1824 and is headquartered in Vienna, Austria.

The Green Organic Dutchman Holdings Ltd. engages in the production, cultivation, processing, and distribution of cannabis and related products. Its products include cannabis plants, cannabis plant seeds, dried cannabis, fresh cannabis, cannabis oils, cannabis topicals, cannabis extracts, and edible cannabis. The company was founded by Scott Skinner and Jeannette VanderMarel in 2012 and is headquartered in Mississauga, Canada.